Additional Supporting Information may be found in the online version of this article.

pbc_24299_sm_SuppFig1.tif32621KSupplementary Figure 1.
pbc_24299_sm_SuppFig2.tif32621KSupplementary Figure 2.
pbc_24299_sm_SuppFig3.tif32621KSupplementary Figure 3.
pbc_24299_sm_SuppFig4.tif1485KSupplementary Figure 4.
pbc_24299_sm_SuppFig5.tif1380KSupplementary Figure 5.
pbc_24299_sm_SuppFig6.tif1459KSupplementary Figure 6.
pbc_24299_sm_SuppMethod.doc38KSupplementary Method.
pbc_24299_sm_SuppTabI.docx25KSupplemental Table I. Representativity of the study cohort with respect to i) cohort of patients with ALL treated following the ALL IC-BFM 2002 protocol in the study period without an available IKZF1 status, ii) validation cohort.
pbc_24299_sm_SuppTabII.docx14KSupplemental Table II. Relative representation of individual IKZF1 isoforms in patients with ALL and in healthy controls.
pbc_24299_sm_SuppTabIII.docx21KSupplemental Table III. Characteristics of patients with IKZF1 alterations (gene deletion or Ik6 overexpression) treated following the ALL IC-BFM 2002 protocol.
pbc_24299_sm_SuppTabIV.docx12KSupplemental Table IV.Sequences of primers and probes used in qPCR for IKZF1 isoforms.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.